News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analysts urge buys on TSMC and CoreWeave citing AI/GPU demand and capacity builds, suggesting re-rating upside for semiconductor and cloud-infrastructure suppliers.
  • Nike flagged as oversold with multi-year lows, dividend yield near 4.6%, and upcoming catalysts prompting a tactical buy-the-dip trade.
  • Assured Guaranty seen as undervalued at sub-1x book with ~6% ROE and path to higher returns, recommending entry near $69.50.
  • Carvana described as moving to scalable profitability with improving cash flow and liquidity, supporting a multiple-expansion trade.
  • IBM pitched as a reset trade focused on free cash flow and mean-reversion into the $260 area over 45 trading days.
  • United Therapeutics valued as a buy while market prices product erosion, entry at market and target near $580 over 180 trading days.

Latest Articles

Goosehead Insurance, Inc. Named to Selling Power Magazine’s 60 Best Companies to Sell For 2026 List

Goosehead Insurance, Inc. Named to Selling Power Magazine’s 60 Best Companies to Sell For 2026 List

Goosehead Insurance, Inc. (NASDAQ: GSHD) was named to Selling Power Magazine's 60 Best Companies to Sell For 2026 list, signaling its excellence in building a high-performing sales culture. The company continues expanding its corporate sales team and geographic footprint across the U.S. to capitalize on growth opportunities in the fragmented person…

RxSight After the Bleed: A Tactical Long From the Bottom

RxSight After the Bleed: A Tactical Long From the Bottom

RxSight has retraced to the low end of its 52-week range after a year of headline risk and sales variability. With 2025 revenue coming in at $134.5M, accelerating procedure counts, a clean balance sheet (no debt) and attractive valuation versus revenue, a disciplined long trade looking for mean reversion and continued adoption makes sense. This is …

Tech Rally, Biotech Slump: Friday’s Biggest Market Cap Movers

Tech Rally, Biotech Slump: Friday’s Biggest Market Cap Movers

Friday’s trading session produced a mix of sharp rallies and notable pullbacks across market caps. Large technology names led gains among mega-cap stocks, while several biotech and small-cap names posted steep declines. The day’s movers span sectors including technology, cybersecurity, streaming, biopharma and industrial services.

AI Developments and Big Tech Deals Drive This Week's Top Stock Moves

AI Developments and Big Tech Deals Drive This Week's Top Stock Moves

This week’s notable market activity was centered on advances in artificial intelligence and a major chip manufacturing agreement. Meta’s release of a new multimodal AI model and an API preview helped lift its shares, while Broadcom rallied after Apple announced a multiyear, multi-billion-dollar manufacturing deal. SK Hynix debuted on Nasdaq, Nvidia…

U.S. Loosens Export Rules for UAE, Easing Access to Military Gear and Advanced Tech

U.S. Loosens Export Rules for UAE, Easing Access to Military Gear and Advanced Tech

The U.S. Department of Commerce has relaxed export controls for the United Arab Emirates, enabling easier shipment of certain military items, commercial satellites and spacecraft, and advanced computing hardware to the UAE government and approved firms. The change moves the UAE into a country grouping that permits expanded license exceptions for mi…

Byrna’s Sales Problem Is the Real Product Risk - A Tactical Short

Byrna’s Sales Problem Is the Real Product Risk - A Tactical Short

Byrna Technologies can build a compelling less-lethal product, but recent results show the harder job is turning product into repeat retail sales. With Q2 revenue down 43% YoY, a $10.4M impairment and production cuts, the risk-reward today favors a tactical short into weakness. Entry $3.95, stop $5.50, target $2.25 for a mid-term trade around 45 tr…

Moody's Moves Prosus Outlook to Positive, Affirms Baa2 Rating

Moody's Moves Prosus Outlook to Positive, Affirms Baa2 Rating

Moody's Ratings has upgraded the outlook on Prosus N.V. to positive from stable while maintaining the company's Baa2 long-term issuer rating. The agency pointed to improved operating profitability across Prosus' ecosystem companies and increasing dividend income from assets beyond Tencent as key factors supporting the change.